Trevi Therapeutics (TRVI) News Today $5.78 -0.27 (-4.46%) Closing price 04:00 PM EasternExtended Trading$5.50 -0.28 (-4.84%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Trevi Therapeutics to Participate in Upcoming April Investor ConferencesApril 3, 2025 | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short InterestApril 3, 2025 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Here's What HappenedTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Time to Sell?April 2, 2025 | marketbeat.comShort Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 23.5%Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,680,000 shares, an increase of 23.5% from the February 28th total of 3,790,000 shares. Approximately 8.1% of the shares of the company are sold short. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 2.5 days.April 2, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $34,630.54 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 26, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Up 5.7% - Should You Buy?Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% Higher - Still a Buy?March 26, 2025 | marketbeat.comRosalind Advisors Inc. Has $4.38 Million Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Rosalind Advisors Inc. raised its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 41.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,062,500 shares of the company's stock after purchMarch 23, 2025 | marketbeat.comHC Wainwright Issues Negative Forecast for TRVI EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst O. Livnat now anticipates that the company will pMarch 22, 2025 | marketbeat.comQ2 EPS Estimates for Trevi Therapeutics Reduced by B. RileyTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Investment analysts at B. Riley lowered their Q2 2025 earnings estimates for Trevi Therapeutics in a research note issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of (March 22, 2025 | marketbeat.comLeerink Partnrs Issues Positive Outlook for TRVI EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for Trevi Therapeutics in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings perMarch 22, 2025 | marketbeat.comB. Riley Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)B. Riley reaffirmed a "buy" rating and issued a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday.March 20, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Earnings BeatTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected EarningsMarch 20, 2025 | marketbeat.comEarnings call transcript: Trevi Therapeutics Q4 2024 reports mixed resultsMarch 20, 2025 | uk.investing.comTREVI THERAPEUTICS Earnings Results: $TRVI Reports Quarterly EarningsMarch 20, 2025 | nasdaq.comHC Wainwright Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)HC Wainwright restated a "buy" rating and set a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday.March 20, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Price Target Cut to $24.00 by Analysts at Needham & Company LLCNeedham & Company LLC decreased their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a report on Wednesday.March 20, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday.March 20, 2025 | marketbeat.comTrevi Therapeutics price target raised to $20 from $11 at B. RileyMarch 19, 2025 | markets.businessinsider.comB.Riley Financial Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)March 19, 2025 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Issues Earnings ResultsTrevi Therapeutics (NASDAQ:TRVI - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01.March 19, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Up 4.4% - Here's WhyTrevi Therapeutics (NASDAQ:TRVI) Trading Up 4.4% - Here's What HappenedMarch 19, 2025 | marketbeat.comTejara Capital Ltd Decreases Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Tejara Capital Ltd decreased its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 36.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 153,739 shares of the company's stock after seMarch 19, 2025 | marketbeat.comTrevi Therapeutics reports Q4 EPS (11c), consensus (12c)March 19, 2025 | markets.businessinsider.comTrevi Therapeutics options imply 7.8% move in share price post-earningsMarch 19, 2025 | markets.businessinsider.comTrevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move ForwardMarch 18, 2025 | marketwatch.comTrevi Therapeutics added to Analyst Current Favorites list at Raymond JamesMarch 18, 2025 | markets.businessinsider.comTrevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comTrevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business UpdatesMarch 18, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Trading Down 3.3% - Here's What HappenedTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 3.3% - Here's WhyMarch 18, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned an average recommendation of "Buy" from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and three have assigned a strong bMarch 18, 2025 | marketbeat.comTrevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past weekMarch 16, 2025 | finance.yahoo.comEquities Analysts Issue Forecasts for TRVI FY2024 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst O. Livnat now forecasts that the company will post earninMarch 14, 2025 | marketbeat.comFarrell Simon Sells 81,313 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) insider Farrell Simon sold 81,313 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 13, 2025 | marketbeat.comTraders Buy Large Volume of Call Options on Trevi Therapeutics (NASDAQ:TRVI)Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders purchased 5,103 call options on the stock. This is an increase of 802% compared to the typical daily volume of 566 call options.March 12, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Given New $20.00 Price Target at OppenheimerOppenheimer increased their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday.March 12, 2025 | marketbeat.comTrevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on WednesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings before the market opens on Wednesday, March 19, Financial Modeling Prep reports.March 12, 2025 | marketbeat.comTrevi Therapeutics price target raised to $20 from $12 at OppenheimerMarch 11, 2025 | markets.businessinsider.comTRVI Stock Soars on Meeting Primary Goal in Chronic Cough StudyMarch 11, 2025 | msn.comTrevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025March 11, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $12.50HC Wainwright increased their price objective on Trevi Therapeutics from $7.50 to $12.50 and gave the stock a "buy" rating in a report on Monday.March 11, 2025 | marketbeat.comTrevi Therapeutics price target raised to $25 from $8 at NeedhamMarch 11, 2025 | markets.businessinsider.comTrevi Shares Climb On Positive Results for Chronic Cough TreatmentMarch 10, 2025 | marketwatch.comTrevi Therapeutics price target raised to $12.50 from $7.50 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comRaymond James Upgrades Trevi Therapeutics (TRVI)March 10, 2025 | msn.comTrevi Therapeutics meets main goal in chronic coughing treatment trial, stock surgesMarch 10, 2025 | msn.comTrevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock JumpsMarch 10, 2025 | benzinga.comTrevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High After Analyst UpgradeTrevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High After Analyst UpgradeMarch 10, 2025 | marketbeat.comTrevi Therapeutics stock soars on positive trial resultsMarch 10, 2025 | in.investing.comTrevi Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesMarch 10, 2025 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond JamesRaymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the stock from $9.00 to $29.00 in a research report on Monday.March 10, 2025 | marketbeat.com Remove Ads Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.630.64▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼54▲TRVI Articles Average Week Remove Ads Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHC News TWST News NAMS News VCEL News MIRM News RXRX News BLTE News EWTX News DNLI News TARS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRVI Stock Free TRVI Stock Alerts